List view / Grid view
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
6 July 2016 | By Victoria White, Digital Content Producer
Scancell has provided an update from the SCIB1 Phase I/II clinical trial in malignant melanoma, the lead programme from the Company’s ImmunoBody platform...
23 June 2016 | By Victoria White, Digital Content Producer
ECHO-301 will evaluate Incyte’s epacadostat with Merck’s pembrolizumab as first-line treatment for patients with advanced or metastatic melanoma...
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
17 June 2016 | By Victoria White, Digital Content Producer
The NHS will receive a discount on the combination treatment agreed between Bristol-Myers Squibb and the Department of Health...
7 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma...
6 June 2016 | By Victoria White, Digital Content Producer
Immunocore has announced positive data from the first in human, Phase I clinical trial of its lead ImmTAC, IMCgp100...
2 June 2016 | By Victoria White, Digital Content Producer
BioNTech has announced the publication of a study that describes the first example of a clinically relevant and systemic mRNA cancer immunotherapy...
11 May 2016 | By Victoria White, Digital Content Producer
The approval of Opdivo + Yervoy represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU)...
3 May 2016 | By Victoria White, Digital Content Producer
NICE has published final draft guidance recommending trametinib in combination with dabrafenib to treat some patients with melanoma...
26 April 2016 | By Victoria White, Digital Content Producer
In an exclusive interview, Erin Seeley of Protea Biosciences discusses Proteomic Mass Spectrometry Imaging and Protea's recently announced license agreement with Yale...
18 April 2016 | By Victoria White, Digital Content Producer
A Opdivo and Yervoy combination regimen demonstrated a two-year OS rate of 69% compared to 53% for Yervoy alone in BRAF wild-type advanced melanoma...
30 March 2016 | By Victoria White
The trial of IMCgp100 will include three Phase I escalation cohorts to determine the optimal dose for the Phase II study, which is expected to start in 2016...
16 March 2016 | By Victoria White
NICE says there is not enough evidence to be able to say whether talimogene laherparepvec is as effective as other drugs used to treat advanced melanoma...
25 January 2016 | By Victoria White
The FDA has approved Opdivo (nivolumab) + Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma...
